Literature DB >> 1412718

Evidence that long-term survival of concordant xenografts is achieved by inhibition of antispecies antibody production.

R Hasan1, J B Van den Bogaerde, J Wallwork, D J White.   

Abstract

Antibody and complement have been shown to be of primary importance in the rejection of hamster heart xenografts by rats. Very high anti-hamster antibody titers were detected at the time of rejection of hamster hearts transplanted into untreated or T cell deficient rats. This study demonstrates a method of inhibiting this antibody production by pulse therapy with cyclophosphamide (CyP) and continuous cyclosporine treatment, resulting in a median survival of the hamster heart of greater than 100 days. Controls and CsA-treated rats reject the transplanted hamster heart in a median of 3 days. CyP as a sole therapy resulted in a median survival of 14 days. Prolonged CyP therapy when combined with CsA was associated with increased death among rat recipients due to infection. Antispecies antibody production was suppressed during CyP and CsA therapy and did not recur after cessation of CyP therapy. Cessation of CsA therapy at 60 and 100 days posttransplantation resulted in subsequent rejection of the xenografts (median survival after cessation of therapy of 11 and 19.5 days, respectively) and was associated with production of rat anti-hamster antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1412718     DOI: 10.1097/00007890-199209000-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells.

Authors:  A Langer; L A Valdivia; N Murase; J Woo; S Celli; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

2.  Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience.

Authors:  K Abu-Elmagd; S Todo; J Fung; J Demetris; J Rakela; A S Rao; S Iwatsuki; T Starzl
Journal:  Clin Transpl       Date:  1994

3.  Human liver xenotransplantation.

Authors:  T E Starzl; A Tzakis; J J Fung; S Todo; I R Marino; A J Demetris
Journal:  Xeno       Date:  1993-09

Review 4.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 5.  The biological basis of and strategies for clinical xenotransplantation.

Authors:  T E Starzl; L A Valdivia; N Murase; A J Demetris; P Fontes; A S Rao; R Manez; I R Marino; S Todo; A W Thomson
Journal:  Immunol Rev       Date:  1994-10       Impact factor: 12.988

Review 6.  New immunosuppressive drugs: mechanistic insights and potential therapeutic advances.

Authors:  A W Thomson; T E Starzl
Journal:  Immunol Rev       Date:  1993-12       Impact factor: 12.988

Review 7.  Prospects of clinical xenotransplantation.

Authors:  T E Starzl; A Tzakis; J J Fung; S Todo; A J Demetris; R Manez; I R Marino; L Valdivia; N Murase
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066

8.  Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells.

Authors:  K Tamura; J Woo; M T Bakri; A W Thomson
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

9.  Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation.

Authors:  M Tanaka; N Murase; Q Ye; W Miyazaki; M Nomoto; H Miyazawa; R Manez; Y Toyama; A J Demetris; S Todo; T E Starzl
Journal:  Transplantation       Date:  1996-09-15       Impact factor: 4.939

10.  Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice.

Authors:  J Woo; T M Wright; B Lemster; D Borochovitz; M A Nalesnik; A W Thomson
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.